Compare MHO & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | TMDX |
|---|---|---|
| Founded | 1976 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.4B |
| IPO Year | 1995 | 2019 |
| Metric | MHO | TMDX |
|---|---|---|
| Price | $127.65 | $111.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $160.00 | $148.22 |
| AVG Volume (30 Days) | 172.4K | ★ 851.2K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | ★ 14.74 | 4.87 |
| Revenue | ★ $4,417,781,000.00 | $605,494,000.00 |
| Revenue This Year | $0.66 | $24.51 |
| Revenue Next Year | $6.97 | $18.72 |
| P/E Ratio | ★ $8.57 | $23.79 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $102.44 | $88.50 |
| 52 Week High | $158.92 | $156.00 |
| Indicator | MHO | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.54 | 48.73 |
| Support Level | $125.38 | $109.43 |
| Resistance Level | $127.81 | $131.86 |
| Average True Range (ATR) | 3.63 | 5.27 |
| MACD | 1.01 | 1.93 |
| Stochastic Oscillator | 91.47 | 67.41 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.